<DOC>
	<DOCNO>NCT01929083</DOCNO>
	<brief_summary>Female sex independent risk factor potentially fatal drug-induced arrhythmia ( irregular heartbeat ) know torsades de pointes ( TdP ) , associate prolongation correct QT ( QTc ) interval electrocardiogram ( ECG ) . Mechanisms increase risk woman well-understood . QTc interval duration show fluctuate throughout phase menstrual cycle . Evidence indicate QTc interval response drug may cause TdP great menses ovulation phase menstrual cycle , serum progesterone concentration low , less luteal phase , serum progesterone concentration high . Additional evidence laboratory suggest progesterone may protective TdP . Specific Aim 1 : Establish influence oral progesterone administration preventive method diminish degree drug-induced QT interval prolongation woman . Working hypothesis : Oral progesterone administration effectively attenuate enhanced drug-induced QT interval response woman . To test hypothesis , progesterone placebo administer crossover fashion woman menses phase menstrual cycle . QTc interval response low-dose ibutilide , drug know lengthen QT interval , assess . The primary endpoint individually-corrected QT interval ( QTcI ) response ibutilide , presence absence progesterone , assess : 1 ) Effect maximum change QTcI , 2 ) Area QTcI interval-time curve ( AUEC ) . At conclusion study , establish oral progesterone administration safe effective method attenuate drug-induced QT interval prolongation .</brief_summary>
	<brief_title>Influence Progesterone Administration Drug-Induced QT Interval Lengthening</brief_title>
	<detailed_description />
	<mesh_term>Death , Sudden</mesh_term>
	<mesh_term>Torsades de Pointes</mesh_term>
	<mesh_term>Long QT Syndrome</mesh_term>
	<mesh_term>Jervell-Lange Nielsen Syndrome</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Ibutilide</mesh_term>
	<criteria>Female Age 2140 year Premenopausal Serum potassium , &lt; 3.6 meq/l Serum magnesium &lt; 1.8 mg/dl Serum hemoglobin &lt; 9.0 mg/dl Serum hematocrit &lt; 26 % Hypertension Coronary artery disease Heart failure Liver disease Kidney disease Serum creatinine &gt; 1.5 mg/dl Taking hormone contraceptive Baseline Bazett 's correct QTc interval &gt; 450 m Family history longQT syndrome , arrhythmia , sudden cardiac death Concomitant use QT prolong drug Pregnancy weight &lt; 45 kg Unwillingness use nonhormonal form birth control study period</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Torsades de pointes</keyword>
	<keyword>Progesterone</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Risk reduction</keyword>
	<keyword>Electrocardiography</keyword>
</DOC>